Predictive Value of the Platelet-To-Lymphocyte Ratio in Diagnosis of Prostate Cancer |
Yuksel, Ozgur Haki
(Department of Urology, Fatih Sultan Mehmet, Research and Training Hospital)
Urkmez, Ahmet (Department of Urology, Fatih Sultan Mehmet, Research and Training Hospital) Akan, Serkan (Department of Urology, Fatih Sultan Mehmet, Research and Training Hospital) Yldirim, Caglar (Department of Urology, Fatih Sultan Mehmet, Research and Training Hospital) Verit, Ayhan (Department of Urology, Fatih Sultan Mehmet, Research and Training Hospital) |
1 | Sonpavde G, Pond GR, Armstrong AJ, et al (2014). Prognostic impact of the neutrophil-to-lymphocyte ratio in men with metastatic castration-resistant prostate cancer. Clin Genitourin Cancer, 12, 317-4. DOI |
2 | Sumbul AT, Sezer A, Abali H, et al (2014). Neutrophil-tolymphocyte ratio predicts PSA response, but notoutcomes in patients with castration-resistant prostate cancer treated withdocetaxel. Int Urol Nephrol, 46, 1531-5. DOI |
3 | Tai CG, Johnson TV, Abbasi A, et al (2014). External validation of the modified glasgow prognostic score for renal cancer. Indian J Urol, 30, 33-7. DOI |
4 | Tanik S, Albayrak S, Zengin K, et al (2014). Is the neutrophillymphocyte ratio an indicator of progression in patients with benign prostatic hyperplasia? Asian Pac J Cancer Prev, 15, 6375-9. DOI |
5 | Templeton AJ, Pezaro C, Omlin A, et al (2014). Simple prognostic score for metastatic castration-resistant prostate cancer with incorporation of neutrophil-to-lymphocyte ratio. Cancer, 120, 3346-2. DOI |
6 | Fujita K, Hosomi M, Nakagawa M, et al (2014). White blood cell count is positively associated with benign prostatic hyperplasia. Int J Urol, 21, 308-2. DOI |
7 | Fujita K, Imamura R, Tanigawa G, et al (2012). Low serum neutrophil count predicts a positive prostate biopsy. Prostate Cancer Prostatic Dis, 15, 386-0. DOI ScienceOn |
8 | Gorelick C, Andikyan V, Mack M, Lee YC, Abulafia (2009). Prognostic significance of preoperative thrombocytosis in patients with endometrial carcinoma in an innercity population. Int J Gynecol Cancer, 19, 1384-9. DOI |
9 | Gueron G, De Siervi A, Vazquez E (2012). Advanced prostate cancer: reinforcing the strings between inflammation and the metastatic behavior. Prostate Cancer Prostatic Dis, 15, 213-1 DOI |
10 | Gungor T, Kanat-Pektas M, Sucak A, Mollamahmutoglu L (2009). The role of thrombocytosis in prognostic evaluation of epithelial ovarian tumors. Arch Gynecol Obstet, 279, 53-6. DOI |
11 | Jarnicki A, Putoczki T, Ernst M (2010). Stat3: linking inflammation to epithelial cancer more than a "gut" feeling? Cell Div, 5, 14. DOI ScienceOn |
12 | Kantoff PW, Higano CS, Shore ND, et al (2010). Sipuleucel-T immunotherapy for castration-resistant prostate cancer. N Engl J Med, 363, 411-2. DOI |
13 | Kramer G, Mitteregger D, Marberger M (2007). Is benign prostatic hyperplasia (BPH) an immune inflammatory disease? Eur Urol, 51, 1202-6. DOI |
14 | Karazanashvili G (2008). Editorial comment on: the relationship between prostate inflammation and lower urinary tract symptoms: examination of baseline data from the REDUCE trial. Eur Urol, 54, 1383-4. DOI |
15 | Keizman D, Gottfried M, Ish-Shalom M, et al (2012). Pretreatment neutrophil-to-lymphocyte ratio in metastatic castration-resistantprostate cancer patients treated with ketoconazole: association with outcome and predictive nomogram. Oncologist, 17, 1508-4. DOI |
16 | Kerpsack JT, Finan MA (2000). Thrombocytosis as a predictor of malignancy in women with a pelvic mass. J Reprod Med, 45, 929-2. |
17 | Li AJ, Madden AC, Cass I, et al (2004). The prognostic significance of thrombocytosis in epithelial ovarian carcinoma. Gynecol Oncol, 92, 211-4. DOI |
18 | Mantovani A, Allavena P, Sica A, Balkwill F (2008). Cancerrelated inflammation. Nature, 454, 436-4. DOI |
19 | McDonald AC, Vira MA, Vidal AC, et al (2014). Association between systemic inflammatory markers and serum prostatespecific antigen in men without prostatic disease - the 2001-2008 national health and nutrition examination survey. Prostate, 74, 561-7. DOI |
20 | Mengus C, Le Magnen C, Trella E, et al (2011). Elevated levels of circulating IL-7 and IL-15 in patients with early stage prostate cancer. J Transl Med, 9, 162. DOI |
21 | Mistry K, Cable G (2003). Meta-analysis of prostatespecific antigen and digital rectal examination as screening tests for prostate carcinoma. J Am Board Fam Pract, 16, 95-1. DOI |
22 | Prins RC, Rademacher BL, Mongoue-Tchokote S, et al (2012). C-reactive protein as an adverse prognostic marker for men with castration-resistant prostate cancer (CRPC): confirmatory results. Urol Oncol, 30, 33-7. DOI ScienceOn |
23 | Nuhn P, Vaghasia AM, Goyal J, et al (2013). Association of pretreatment neutrophil-to-lymphocyte ratio (NLR) and overall survival (OS) in patients with metastatic castrationresistantprostate cancer (mCRPC) treated with first-line docetaxel. BJU Int, e-pub ahead of print, doi: 10.1111/bju.12531. DOI |
24 | Palapattu GS, Sutcliffe S, Bastian PJ, et al (2005). Prostate carcinogenesis and inflammation: emerging insights. Carcinogenesis, 26, 1170-1. |
25 | Pond GR, Armstrong AJ, Wood BA, et al (2012). Ability of C-reactive protein to complement multiple prognostic classifiers in men with metastatic castration resistant prostate cancer receiving docetaxel-based chemotherapy. BJU Int, 110, 461-8. DOI ScienceOn |
26 | Roehl KA, Antenor JA, Catalona WJ (2002). Serial biopsy results in prostate cancer screening study. J Urol, 167, 2435-9. DOI |
27 | Schaider H, Oka M, Bogenrieder T, et al (2003). Differential response of primary and metastatic melanomas to neutrophils attracted by IL-8. Int J Cancer, 103, 335-3. DOI |
28 | Shafique K, Proctor MJ, McMillan DC, et al (2012). Systemic inflammation and survival of patients with prostate cancer: evidence from the glasgow inflammation outcome study. Prostate Cancer Prostatic Dis, 15, 195-1. DOI |
29 | Shafique K, Proctor MJ, McMillan DC, et al (2013). The modified glasgow prognostic score in prostate cancer: results from a retrospective clinical series of 744 patients. BMC Cancer, 13, 292. DOI |